Recent research has uncovered that targeted PD-L1 siRNA can effectively enhance cancer immunotherapy outcomes by suppressing tumor defense mechanisms within the immune microenvironment. This novel approach focuses on disrupting PD-L1-mediated immune evasion, which allows tumors to escape immune detection. The study employed advanced RNA interference technologies to downregulate PD-L1 expression, thereby boosting the efficacy of immunotherapeutic agents. These findings open new avenues for combining siRNA treatments with existing cancer immunotherapies to overcome resistance.